Lohberger Andrea, Coste Alix T, Sanglard Dominique
Institute of Microbiology, University Hospital Lausanne and University Hospital Center, Lausanne, Switzerland.
Eukaryot Cell. 2014 Jan;13(1):127-42. doi: 10.1128/EC.00245-13. Epub 2013 Nov 15.
Azoles are widely used in antifungal therapy in medicine. Resistance to azoles can occur in Candida albicans principally by overexpression of multidrug transporter gene CDR1, CDR2, or MDR1 or by overexpression of ERG11, which encodes the azole target. The expression of these genes is controlled by the transcription factors (TFs) TAC1 (involved in the control of CDR1 and CDR2), MRR1 (involved in the control of MDR1), and UPC2 (involved in the control of ERG11). Several gain-of-function (GOF) mutations are present in hyperactive alleles of these TFs, resulting in the overexpression of target genes. While these mutations are beneficial to C. albicans survival in the presence of the antifungal drugs, their effects could potentially alter the fitness and virulence of C. albicans in the absence of the selective drug pressure. In this work, the effect of GOF mutations on C. albicans virulence was addressed in a systemic model of intravenous infection by mouse survival and kidney fungal burden assays. We engineered a set of strains with identical genetic backgrounds in which hyperactive alleles were reintroduced in one or two copies at their genomic loci. The results obtained showed that neither TAC1 nor MRR1 GOF mutations had a significant effect on C. albicans virulence. In contrast, the presence of two hyperactive UPC2 alleles in C. albicans resulted in a significant decrease in virulence, correlating with diminished kidney colonization compared to that by the wild type. In agreement with the effect on virulence, the decreased fitness of an isolate with UPC2 hyperactive alleles was observed in competition experiments with the wild type in vivo but not in vitro. Interestingly, UPC2 hyperactivity delayed filamentation of C. albicans after phagocytosis by murine macrophages, which may at least partially explain the virulence defects. Combining the UPC2 GOF mutation with another hyperactive TF did not compensate for the negative effect of UPC2 on virulence. In conclusion, among the major TFs involved in azole resistance, only UPC2 had a negative impact on virulence and fitness, which may therefore have consequences for the epidemiology of antifungal resistance.
唑类药物在医学抗真菌治疗中被广泛使用。白色念珠菌对唑类药物产生耐药性主要是通过多药转运蛋白基因CDR1、CDR2或MDR1的过表达,或者通过编码唑类药物靶点的ERG11的过表达。这些基因的表达受转录因子(TFs)TAC1(参与控制CDR1和CDR2)、MRR1(参与控制MDR1)和UPC2(参与控制ERG11)的调控。这些转录因子的高活性等位基因中存在几个功能获得性(GOF)突变,导致靶基因的过表达。虽然这些突变有利于白色念珠菌在抗真菌药物存在的情况下存活,但它们的作用可能会在没有选择性药物压力的情况下改变白色念珠菌的适应性和毒力。在这项研究中,通过小鼠存活和肾脏真菌负荷试验,在静脉感染的系统模型中研究了功能获得性突变对白色念珠菌毒力的影响。我们构建了一组具有相同遗传背景的菌株,其中高活性等位基因在其基因组位点以一个或两个拷贝重新引入。获得的结果表明,TAC1和MRR1的功能获得性突变对白色念珠菌的毒力均无显著影响。相比之下,白色念珠菌中两个高活性UPC2等位基因的存在导致毒力显著降低,与野生型相比,肾脏定植减少。与对毒力的影响一致,在体内与野生型的竞争实验中观察到具有UPC2高活性等位基因的分离株适应性降低,但在体外未观察到。有趣的是,UPC2的高活性延迟了白色念珠菌被小鼠巨噬细胞吞噬后的丝状化,这可能至少部分解释了毒力缺陷。将UPC2功能获得性突变与另一个高活性转录因子结合并不能补偿UPC2对毒力的负面影响。总之,在参与唑类耐药性的主要转录因子中,只有UPC2对毒力和适应性有负面影响,因此这可能对抗真菌耐药性的流行病学产生影响。